Product
Teprotumumab
Aliases
HZN-001
6 clinical trials
4 indications
Indication
Graves' DiseaseIndication
Graves OphthalmopathyIndication
Graves diseaseIndication
Graves' OphthalmopathyClinical trial
A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Teprotumumab in Participants With Moderate-to-Severe Active Thyroid Eye DiseaseStatus: Recruiting, Estimated PCD: 2025-09-15
Clinical trial
A Phase 1b, Open-label, Multicenter Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Formulations of a Single Subcutaneous Dose of Teprotumumab Followed by Multiple Intravenous Doses of TEPEZZA in Participants With Thyroid Eye DiseaseStatus: Completed, Estimated PCD: 2023-02-28
Clinical trial
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid DysfunctionStatus: Recruiting, Estimated PCD: 2026-05-12
Clinical trial
A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of TeprotumumabStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
Phase 3b, Multicenter, Open-label, Single-Arm Expanded Access Protocol of TEPROTUMUMAB (HZN-001)Status:
Clinical trial
Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye DiseaseStatus: Completed, Estimated PCD: 2020-06-08